and non-Hodgkin lymphoma is a cancer of lymphocytes. WM cells have features of both plasma cells and lymphocytes. Lymphocytes are one of the main types of white blood cells in the immune system. They ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Therapy-related B-cell acute lymphoblastic leukemia (B-ALL), a rare form of acute lymphoblastic leukemia (ALL), may develop in patients receiving cytotoxic treatments for a prior malignancy, according ...

Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for CLL and ...

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

Lead Author Abstract Title Presentation Details Pro. Jie Hu 67P - A Phase II Study of SunvozertinibCombined with Anlotinib in ...

-- Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete ...